Investor Alert

Market Pulse Archives

June 21, 2018, 4:08 p.m. EDT

FDA approves first implantable glucose monitor

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Senseonics Holdings Inc. (SENS)

or Cancel Already have a watchlist? Log In

By Jeremy C. Owens


The Food and Drug Administration on Thursday approved the first implantable glucose monitoring system for diabetics, a product made by Senseonics Holdings Inc. /zigman2/quotes/209443072/composite SENS -6.04% The system requires a small sensor to be surgically implanted in an outpatient procedure; the sensor uses light readings to relay blood-sugar levels to a mobile app for 90 days. "The FDA is committed to advancing novel products that leverage digital technology to improve patient care," FDA Commissioner Scott Gottlieb said in Thursday's announcement . "These technologies allow patients to gain better control over their health." Senseonic shares were halted ahead of the announcement and reopened less than a half-hour before the close, bounced between gains of 1% and 5% in heavy-volume trading into the close, when it was up 1.9%.

US : U.S.: NYSE American
$ 1.71
-0.11 -6.04%
Volume: 17.15M
May 13, 2021 4:00p
P/E Ratio
Dividend Yield
Market Cap
$778.81 million
Rev. per Employee

Get news alerts on Senseonics Holdings Inc. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.